Timing evolution of lobular breast cancer through phylogenetic analysis
Danai Fimereli,
David Venet,
Mattia Rediti,
Bram Boeckx,
Marion Maetens,
Samira Majjaj,
Ghizlane Rouas,
Caterina Marchio,
Francois Bertucci,
Odette Mariani,
Maria Capra,
Giuseppina Bonizzi,
Federica Contaldo,
Christine Galant,
Gert Van den Eynden,
Roberto Salgado,
Elia Biganzoli,
Anne Vincent-Salomon,
Giancarlo Pruneri,
Denis Larsimont,
Diether Lambrechts,
Christine Desmedt,
David N. Brown,
Françoise Rothé,
Christos Sotiriou
Affiliations
Danai Fimereli
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
David Venet
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Mattia Rediti
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Bram Boeckx
Laboratory of Translational Genetics, VIB Center for Cancer Biology, Leuven, Belgium; Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
Marion Maetens
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
Samira Majjaj
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Ghizlane Rouas
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Caterina Marchio
Department of Medical Sciences, University of Turin, Turin, Italy; FPO-IRCCS Candiolo Cancer Institute, Candiolo, Italy
Department of Pathology, Institut Curie, Paris Sciences Lettres Research University, Paris, France
Maria Capra
Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Milan, Italy
Giuseppina Bonizzi
Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Milan, Italy
Federica Contaldo
Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Milan, Italy
Christine Galant
Department of Pathology, Cliniques Universitaires Saint Luc, Brussels, Belgium; IREC, Université Catholique de Louvain, Brussels, Belgium
Gert Van den Eynden
Department of Pathology, Sint Augustinus, Wilrijk, Belgium
Roberto Salgado
Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Centre, Melbourne, Australia
Elia Biganzoli
Department of Biomedical and Clinical Sciences (DIBIC) “L. Sacco” & DSRC, LITA Vialba campus, University of Milan, Milan, Italy
Anne Vincent-Salomon
Department of Pathology, Institut Curie, Paris Sciences Lettres Research University, Paris, France
Giancarlo Pruneri
Division of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; School of Medicine, University of Milan, Milano, Milan, Italy
Denis Larsimont
Department of Pathology, Institut Jules Bordet, Brussels, Belgium
Diether Lambrechts
Laboratory of Translational Genetics, VIB Center for Cancer Biology, Leuven, Belgium; Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
Christine Desmedt
Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
David N. Brown
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Françoise Rothé
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Christos Sotiriou
J.-C. Heuson Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Corresponding author at: Breast Cancer Translational Research Laboratory (BCTL), Université Libre de Bruxelles, Institut Jules Bordet, Rue Meylemeersh 90, 1070 Anderlecht, Belgium.
Summary: Background: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood. Methods: We retrospectively identified 38 ILC patients from the tissue banks of six European institutions. DNA extracted from patient matched primary and metastatic FFPE tissue blocks was whole genome sequenced to compute somatic copy number aberrations. This, in turn, was used to infer the evolutionary history of these patients. Findings: The data show different metastatic seeding patterns, with both an early and late divergence of the metastatic lineage observed in ILC. Additionally, cascading dissemination from a metastatic precursor was a dominant rule. Alterations in key cancer driver genes, such as TP53 or CCND1, were acquired early while additional aberrations were present only in the metastatic branch. In about 30% of the patients, the metastatic lineage harboured less aberrations than the primary tumour suggesting a period of tumour dormancy or prolonged adaptation at the distant site. This phenomenon was mostly observed in tumours from de novo metastatic patients. Interpretation: Our results provide insights into ILC evolution and offer potential paths for optimised ILC care. Funding: This work has received financial support from Les Amis de l'Institut Bordet, MEDIC, the Breast Cancer Research Foundation (BCRF) and the Belgian Fonds National de la Recherche Scientifique (F.R.S-FNRS).